| Literature DB >> 31116231 |
Yi Liao1, ChengLiang Huang1, JianRong Wang1, XianMing Fan1.
Abstract
The relationship between surfactant-associated protein D polymorphisms and chronic obstructive pulmonary disease risk remains controversial. This article is the first to systematically evaluate this relationship. A comprehensive worldwide search was conducted for relevant literature on surfactant-associated protein D gene mutations and chronic obstructive pulmonary disease risk prediction. Study quality was evaluated using the Newcastle-Ottawa scale. After four genetic models (the allele, additive, recessive, and dominant models) were identified, odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) were applied in this meta-analysis. The meta-analysis included 659 individuals in the case group and 597 in the control group. In the Asian population, none of the four genetic models revealed any significant association between rs2243639 genotype and the risk of chronic obstructive pulmonary disease. In Caucasians, however, the recessive model exhibited significant risk associated with rs2243639. Furthermore, there was a significant association between rs721917 genotype and the risk of chronic obstructive pulmonary disease in the Asian population. In contrast, none of the four gene models revealed any significant risk associated with this gene in the Caucasian population. This meta-analysis suggests that rs2243639 is not related to the risk of chronic obstructive pulmonary disease in the Asian population but is related to this risk in the Caucasian population. Regarding rs721917, the T allele may increase the risk of chronic obstructive pulmonary disease in the Asian population.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31116231 PMCID: PMC6512347 DOI: 10.6061/clinics/2019/e855
Source DB: PubMed Journal: Clinics (Sao Paulo) ISSN: 1807-5932 Impact factor: 2.365
Figure 1Flow chart of study selection based on the inclusion criteria.
Quality assessment of the studies included in the meta-analysis.
| First author | Selection | Comparability | Exposure | Total score | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 1 | 2 | 1 | 2 | 3 | ||
| Ou et al. [12] | ☆ | ☆ | - | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | 8 |
| Shakoori et al. [13] | ☆ | ☆ | ☆ | ☆ | ☆ | - | ☆ | ☆ | ☆ | 7 |
| Issac et al. [14] | ☆ | ☆ | - | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | 8 |
| Fakih et al. [15] | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | 8 |
| Wu [16] | ☆ | ☆ | - | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | 8 |
| Wu [17] | ☆ | ☆ | - | ☆ | ☆ | - | ☆ | ☆ | ☆ | 7 |
Selection: 1. Whether the case is sufficiently defined (if some independent validation was required, one star); 2. Whether the case is representative (if yes, one star); 3. The choice of the control (if they were community controls, one star); 4. Definition of control (if they had no history and new occurrence, one star). Comparability: 1. The study controlled for the influence of age (if yes, one star); 2. The study also controlled other important confounding factors such as gender and smoking history (if yes, one star). Exposure: 1. Determination of exposure (if by reliable method, one star); 2. Same method of ascertainment for cases and controls (if yes, one star); 3. No response rate (if the two groups had the same nonresponse rate, one star).
Egger’s linear regression test to measure funnel plot asymmetry.
| SNP | Group | P | |||
|---|---|---|---|---|---|
| A | AA | AA | AA+AB | ||
| rs2243639 | All (n=4) | 0.610 | 0.425 | 0.040 | 0.620 |
| Asian (n=3) | 0.689 | 0.899 | 0.280 | 0.677 | |
| Caucasian (N=1) | - | - | - | - | |
| rs721917 | All (n=5) | 0.375 | 0.384 | 0.715 | 0.634 |
| Asian (n=4) | 0.457 | 0.221 | 0.828 | 0.319 | |
| Caucasian (N=1) | - | - | - | - | |
Frequency of the rs2243639 and rs721917 polymorphisms in different populations.
| SNP | Author | Race | Case group | Control group | HWE ( | MAF | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| AA | AB | BB | AA | AB | BB | |||||
| rs2243639 | Wu [16] | Asian | 87 | 27 | 3 | 89 | 24 | 4 | 0.16 | 0.14 |
| Ou et al. [12] | Asian | 133 | 53 | 6 | 76 | 45 | 7 | 0.92 | 0.19 | |
| Shakoori et al. [13] | Asian | 16 | 81 | 14 | 15 | 61 | 13 | <0.05 | 0.49 | |
| Issac et al. [14] | Caucasian | 18 | 36 | 9 | 13 | 10 | 2 | 0.97 | 0.39 | |
| rs721917 | Ou et al. [12] | Asian | 86 | 81 | 25 | 43 | 62 | 22 | 0.38 | 0.37 |
| Shakoori et al. [13] | Asian | 18 | 56 | 6 | 16 | 51 | 18 | <0.05 | 0.47 | |
| Fakih et al. [15] | Caucasian | 17 | 35 | 10 | 28 | 64 | 23 | 0.22 | 0.46 | |
| Wu [16] | Asian | 18 | 66 | 33 | 9 | 60 | 48 | 0.10 | 0.38 | |
| Wu [17] | Asian | 15 | 61 | 34 | 14 | 42 | 50 | 0.28 | 0.37 | |
HWE: Hardy-Weinberg equilibrium
MAF: Minimum allele frequency
Main characteristics of the studies included in this meta-analysis.
| Age | Sex | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case group | Control group | |||||||||||
| Author (year) | Race | Case group inclusion criteria | Control group inclusion criteria | Control source | Gene detection method | Case group | Control group | Male | Female | Male | Female | Smoking status ( |
| Ou et al. (2015) [12] | Asian | FEV1/FVC<70% (GOLD stage 1 and higher) | Healthy | HB | PCR | 68.6±11.4 | 58.3±12.8 | 192 | 0 | 128 | 0 | |
| Shakoori et al. (2012) [13] | Asian | FEV1/FVC<70% (GOLD stage 1 and higher) | Healthy | PB | PCR | 61±13 | 37±11 | 115 | 0 | 106 | 0 | |
| Issac et al.(2014) [14] | Caucasian | FEV1/FVC<70% (GOLD stage 1 and higher) | Healthy | HB | PCR | 56.81±9.72 | 54.92±7.12 | 63 | 0 | 25 | 0 | |
| Fakih et al. (2018) [15] | Caucasian | FEV1/FVC<70% (GOLD stage 1 and higher) | Healthy | PB | PCR | 62 (50, 71)* | 36 (23, 49)* | 52 | 38 | 87 | 132 | |
| Wu (2015) [16] | Asian | FEV1/FVC<70% (GOLD stage 1 and higher) | Healthy | PB | PCR | 66.13±5.28 | 66.03±7.40 | 104 | 13 | 97 | 20 | |
| Wu (2016) [17] | Asian | FEV1/FVC<70% (GOLD stage 1 and higher) | Healthy | PB | PCR | 71.73±8.63 | 69.80±8.37 | 97 | 13 | 87 | 19 | |
HB: hospital-based, PB: population-based, PCR: Polymerase chain reaction *All values are expressed as median (Q1;Q3); Q, quartile.
Figure 2Forest plots of the association between the rs2243639 polymorphism and the risk of COPD (A, allelic model; B, additive model; C, recessive model; D, dominant model).
Results of the meta-analysis for primary SPD SNP polymorphisms associated with the risk of COPD.
| SNP | Gene model | Group | OR (95% CI) | Analysis model | ||
|---|---|---|---|---|---|---|
| rs2243639 | A | Asian (N=3) | 0.337 | 1.14 (0.87-1.51) | 18.8 | R |
| Caucasian (N=1) | 0.070 | 0.52 (0.25-1.06) | - | R | ||
| all (N=4) | 0.976 | 0.99 (0.69-2.68) | 55.6 | R | ||
| AA | Asian (N=3) | 0.378 | 1.36 (0.69-2.69) | 0 | F | |
| Caucasian (N=1) | 0.172 | 0.31 (0.06-1.67) | - | F | ||
| all (N=4) | 0.846 | 1.06 (0.58-1.96) | 12.9 | F | ||
| AA | Asian (N=3) | 0.544 | 1.13 (0.76-1.69) | 28.1 | R | |
| Caucasian (N=1) | 0.041 | 0.37 (0.14-0.96) | - | R | ||
| all (N=4) | 0.692 | 0.90 (0.53-1.53) | 61.3 | R | ||
| AA+AB | Asian (N=3) | 0.312 | 1.36 (0.75-2.49) | 0 | F | |
| Caucasian (N=1) | 0.428 | 0.52 (0.10-2.60) | - | F | ||
| all (N=4) | 0.539 | 1.19 (0.68-2.07) | 0 | F | ||
| rs721917 | A | Asian (N=4) | <0.001 | 1.44 (1.20-1.73) | 0 | F |
| Caucasian (N=1) | 0.532 | 1.15 (0.74-1.78) | - | F | ||
| all (N=5) | <0.001 | 1.39 (1.18-1.65) | 0 | F | ||
| AA | Asian (N=4) | 0.001 | 2.10 (1.38-3.21) | 0 | F | |
| Caucasian (N=1) | 0.494 | 1.40 (0.54-3.63) | - | F | ||
| all (N=5) | 0.001 | 1.96 (1.34-2.89) | 0 | F | ||
| AA | Asian (N=4) | 0.017 | 1.48 (1.07-2.05) | 0 | F | |
| Caucasian (N=1) | 0.655 | 1.17 (0.58-2.37) | - | F | ||
| all (N=5) | 0.018 | 1.42 (1.06-1.91) | 0 | F | ||
| AA+AB | Asian (N=4) | <0.001 | 1.86 (1.37-2.54) | 0 | F | |
| Caucasian (N=1) | 0.529 | 1.30 (0.57-2.94) | - | F | ||
| all (N=5) | <0.001 | 1.78 (1.33-2.38) | 0 | F |
OR, odds ratio; CI, confidence interval; R, random effects model; F, fixed effects model.
Figure 3Forest plots of the association between the rs721917 polymorphism and the risk of COPD (A, allelic model; B, additive model; C, recessive model; D, dominant model).